


CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EV 336627002 US

Date of Deposit: December 17, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Tia B. Zimmerman

PATENT
Docket No. 251502007410

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Maria Dolors FERNANDEZ FORNER et al.

Serial No.: Not Yet Assigned

Filing Date: Concurrently Herewith

For: NOVEL QUINUCLIDINE
DERIVATIVES AND MEDICINAL
COMPOSITIONS CONTAINING THE
SAME

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office

Action, directed to the related application Serial Number 10/047,464, filed January 14, 2002, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- ☒ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of ___ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of ___ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the fee transmittal is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **251502007410**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: December 17, 2003

Respectfully submitted,

By: _____

Kimberly A. Bolin
Registration No. 44,546

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5470
Facsimile: (650) 494-0792

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number: 251502007410	Application Number: Not Yet Assigned
	Applicant Maria Dolores FERNANDEZ FORNER et al.	
	Filing Date Concurrently Herewith	Group Art Unit: Not Yet Assigned
	Mailing Date December 17, 2003	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	08/05/1997	5,654,314	Banholzer et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	2.	03/27/1991	EP 0 418 716	Europe			
	3.	04/24/1991	EP 0 424 021	Europe			Abstract
	4.	03/27/1970	FR 2012964	France			
	5.	01/20/1971	GB 1219606	Great Britain			Equivalent to FR 2012964
	6.	04/04/1991	WO 91/04252	WIPO			Equivalent to EP 0 418 716
	7.	7/12/2001	WO 01/50080 A2	WIPO			Abstract
	8.	7/12/2001	WO 01/50080 A3	WIPO			Abstract

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	9.	6001 Chemical Abstracts, Columbus, Ohio, US. Volume 104(19). XP-002128290, Page 659. (1 page total).
	10.	Burtner, R. and Cusic, J. W. (1943). "Antispasmodics, II. Basic Esters of Some Polynuclear Carboxylic Acids," <i>J. Am. Chem. Soc.</i> 65:1582-1585.
	11.	Cohen, V. I. et al. (1992). "Synthesis and Receptor Affinities of New 3-Quinuclidinyl α -Heteroaryl- α -aryl- α -Hydroxyacetates," <i>J. Pharm Sciences</i> 81:326-329.
	12.	Davis, M. A. et al. (1963). "New Psychotropic Agents. VI. Basic Esters of 5-Hydroxydibenzo[a,d]cycloheptadiene-5-carboxylic Acid," <i>J. Med. Chem</i> 6:513-516.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Docket Number: 251502007410	Application Number: Not Yet Assigned
		Applicant Maria Dolores FERNANDEZ FORNER et al.	
		Filing Date Concurrently Herewith	Group Art Unit: Not Yet Assigned
		Mailing Date December 17, 2003	
13.		Davis, M. A. et al (1964). "Anticonvulsants. I. Dibenzo[a,d]cycloheptadiene-5-carboxamide and Related Compounds," <i>J. Med. Chem.</i> 7:88-94.	
14.		Grob, C. A. and Brenneisen, P. (1958). "Die Synthese von 4-Brom- und 4-Hydroxy-Chinuclidin," <i>Helv. Chim. Acta</i> 41:1184-1191.	
15.		Heacock, R.A. et al. (1958). "Materials and Methods," <i>The Annals of Applied Biology</i> , Marsh, R. W. and Thomas, I, eds, Cambridge at the University Press, Volume 46, pp. 356-365.	
16.		Konzett, H. and Rössler, R. (1940). "Versuchsanordnung zu Untersuchungen an der Bronchialmuskulatur," <i>Arch. Exp. Path. Pharmacol.</i> 195:71-74.	
17.		Kumazawa, T. et al. (1994). "Inhibitors of Acyl-CoA:Cholesterol Acyltransferase. 1. Synthesis and Hypocholesterolemic Activity of Dibenzo[b,e]oxepin-11-carboxanilides," <i>J. Med. Chem.</i> 37(6): 804-810.	
18.		Larsson, L. et al. (1974). "The Hydrogen Bond Condition in Some Anticholinergic Esters of Glycolic Acids. I," <i>Acta Pharm. Suec.</i> 11(3):304-308.	
19.		May, E. L and Mossetig, E. (1948). "Studies in the Anthracene Series. V. A Novel Rearrangement in the Reaction of Halomethyl Ketones with Secondary Amines," <i>J. Am. Chem. Soc.</i> 70: 1077-1079.	
20.		Meyers, A. I. et al. (1980). "Resolution of α -Substituted Mandelic Acids via Chiral Oxazolines Using Pressurized Chromatography," <i>J. Org. Chem.</i> 45(14): 2912-2914.	
21.		Nyberg, K. et al. (1970). "Investigations of Dithienylglycolic Esters," <i>Acta Chem. Scand.</i> 24:1590-1596.	
22.		Rigaudy, J. et al. (1959). "Cétones Dérivées du Dibenzo [a,d] cycloheptadiène. La Dibenzo-2-,3-6,7 Cycloheptadiènedione-4,5," <i>Bull. Soc. Chim. France.</i> 638-643.	
23.		Ringdahl, R. et al. (1979). "Facile Preparation of the Enantiomers of 3-Acetoxyquinuclidinol," <i>Acta Pharm Suec.</i> 16:281-283.	
24.		Sestanj, K. (1971). "A Facile Formation of Dibenzo[a,b]cycloheptenylium Ion by Decarbonylation. Color Reactions of the Cyheptaminde Metabolites," <i>Can. J. Chem.</i> 49:664-665.	
25.		Ueda, I. (1975). "The Rearrangement of 10-Bromo-10, 11-Dihydrodibenzo[b,f]thiepin-11-one and Related Compounds in an Alkaline Solution," <i>Bulletin of the Chemical Society of Japan</i> 48(8):2306-2309.	
26.		Waelbroek, M. et al. (1990). "Binding of Selective Antagonists to Four Muscarinic Receptors (M1 to M4) in Rat Forebrain," <i>Mol. Pharmacol.</i> 38:267-273.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number: 251502007410	Application Number: Not Yet Assigned
	Applicant Maria Dolores FERNANDEZ FORNER et al.	
	Filing Date: Concurrently Herewith	Group Art Unit: Not Yet Assigned
	Mailing Date: December 17, 2003	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	09/23/1980	4,224,332	Gueremy et al.			
	2.	02/17/1987	4,644,033	Gnanou and Hild			
	3.	06/27,1989	4,843,074	Rzeszotarski et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
	4.	06/28/1982	178679	Hungary			Abstract only	
	5.	12/11/1996	EP 0 747 355	Europe				
	6.	10/15/1997	EP 0 801 067	Europe				
	7.	03/19/1992	WO 92/04345	WIPO				

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.